



ASX ANNOUNCEMENT

Lumos Secures Distribution for FebriDx® in Romania

MELBOURNE, Australia (30 July 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has executed a new exclusive distribution agreement with Alpha Medical for the sale of FebriDx® in Romania.

FebriDx® is a rapid, point of care diagnostic which aids in the differentiation between bacterial infection and non-bacterial etiology. Alpha Medical is a Romanian medical device distributor that supplies primary care, urgent care and hospitals with a range of medical equipment and consumables. Established in 2001, the company represents leading international healthcare brands and provides product support and servicing across Romania. Supported by a team of more than 25 sales specialists, the company services over 500 customers, offering a portfolio of state-of-the-art technologies that deliver comprehensive healthcare solutions across both public and private medical environments.

Under the new agreement, Alpha Medical will oversee sales, distribution and inventory management of FebriDx® throughout Romania, supported by its established logistics network and customer relationships. Alpha Medical has placed an initial stocking order to support the immediate availability of FebriDx® for its customers.

Lumos continues to build a broad European distribution network for FebriDx®, with existing agreements already in place through Henry Schein across multiple geographies, including the UK, Spain, Portugal and the Netherlands. The addition of Interlux for the Baltic region, covering Lithuania, Estonia and Latvia (ASX: 18 December 2025) further strengthened this footprint, and the appointment of Alpha Medical now broadens Lumos’ European reach into Romania. These partnerships support Lumos’ strategy of expanding access to FebriDx® through experienced regional distribution partners across Europe.

Commenting on the announcement, Doug Ward, Managing Director of Lumos Diagnostics said: *“We are pleased to further expand our European distribution network with Alpha Medical in Romania. Building on our existing relationships across the region, this partnership will help broaden access to FebriDx® and support our continued commercial growth across Europe.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598